Skip to main content

Advertisement

Fig. 6 | BMC Cancer

Fig. 6

From: Utilizing native fluorescence imaging, modeling and simulation to examine pharmacokinetics and therapeutic regimen of a novel anticancer prodrug

Fig. 6

Tumor burden in implanted 4T1 murine mammary tumors following CNOB administration via tail vein. ChrR6 was delivered iv using SL7838 bacteria carrying the gene encoding this enzyme, controlled by the lac promoter; IPTG was used when activation of the gene was required. Tumor burden was measured on the indicated days following CNOB injection (10 mg/kg in three 3.3 mg/kg daily doses). Data represent mean value ± standard deviation (SD) (n = 5). See Figure for the symbols

Back to article page